Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Lebrikizumab · Ebglyss, MILR-1444A

Monoclonal antibody · Antagonist of interleukin-13 (IL13) · developed by Eli Lilly And Co

Approved FDA, Sep 2024
LLY Developer

What is Lebrikizumab?

Lebrikizumab-lbkz is a humanized IgG4 monoclonal antibody that binds IL-13 and inhibits its signaling through the IL-4Rα/IL-13Rα1 receptor complex while allowing IL-13 to bind IL-13Rα2 for clearance. It reduces IL-13-induced proinflammatory cytokines, chemokines, and IgE.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ebglyss, MILR-1444A, PRO-301444
Drug type
Monoclonal antibody
Targets
interleukin-13 (IL13)
Mechanism
Antagonist of interleukin-13 (IL13)
Pathways
Type 2 inflammation, IL-13 signaling
Therapy area
Dermatology
Developer
Eli Lilly And Co (LLY)
FDA status
Approved as Ebglyss (September 13, 2024), BLA761306 · FDA label
UNII
U9JLP7V031

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 9, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Atopic Dermatitis

More from Eli Lilly And Co

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3 Clazakizumab Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Lebrikizumab

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.